Search research articles
Contact Us
Filters
Showing results (21-30 of 68) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2002
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
Martee L Hensley, Robert Maki, E Venkatraman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2015
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Lesley Seymour, Susan Groshen, Gary L Rosner, et al.
Gynecologic Oncology
|
December 1, 2009
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
Roisin O'Cearbhaill, Qin Zhou, Alexia Iasonos, et al.
Cancer Chemotherapy and Pharmacology
|
April 16, 2003
A phase I trial of perillyl alcohol in patients with advanced solid tumors
Christopher G Azzoli, Vincent A Miller, Kenneth K Ng, et al.
Cancer Investigation
|
November 9, 2016
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer
Brian Y Park, Rachel N Grisham, Bjørnar den Hollander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2014
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials
David M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Oncotarget
|
February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
David M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Nuclear Medicine and Biology
|
May 14, 2020
Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation
Brandon Nemieboka, Sai Kiran Sharma, Thapi Dharma Rao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2007
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study
David R Spriggs, Mark F Brady, Luis Vaccarello, et al.
Investigational New Drugs
|
October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
Andrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 68) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2002
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
Martee L Hensley, Robert Maki, E Venkatraman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2015
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Lesley Seymour, Susan Groshen, Gary L Rosner, et al.
Gynecologic Oncology
|
December 1, 2009
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
Roisin O'Cearbhaill, Qin Zhou, Alexia Iasonos, et al.
Cancer Chemotherapy and Pharmacology
|
April 16, 2003
A phase I trial of perillyl alcohol in patients with advanced solid tumors
Christopher G Azzoli, Vincent A Miller, Kenneth K Ng, et al.
Cancer Investigation
|
November 9, 2016
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer
Brian Y Park, Rachel N Grisham, Bjørnar den Hollander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2014
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials
David M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Oncotarget
|
February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
David M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Nuclear Medicine and Biology
|
May 14, 2020
Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation
Brandon Nemieboka, Sai Kiran Sharma, Thapi Dharma Rao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2007
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study
David R Spriggs, Mark F Brady, Luis Vaccarello, et al.
Investigational New Drugs
|
October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
Andrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Page
of 7